Detalles de la búsqueda
1.
Oteseconazole versus fluconazole for the treatment of severe vulvovaginal candidiasis: a multicenter, randomized, double-blinded, phase 3 trial.
Antimicrob Agents Chemother
; 68(1): e0077823, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38095426
2.
Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Diabetes Obes Metab
; 26(3): 901-910, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100147
3.
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trial.
Diabetes Obes Metab
; 26(7): 2774-2786, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38618970
4.
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
BMC Med
; 21(1): 376, 2023 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37775744
5.
Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Oncologist
; 26(7): e1110-e1124, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33893689
6.
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients.
Breast Cancer Res Treat
; 186(3): 687-697, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33634417
7.
YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
Br J Cancer
; 123(6): 1000-1011, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572172
8.
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing.
Chin J Cancer Res
; 32(2): 149-162, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410793
9.
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
Chin J Cancer Res
; 32(3): 370-382, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32694901
10.
Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Cancer Sci
; 110(4): 1420-1430, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30724426
11.
STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Cancer Sci
; 109(10): 3305-3315, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30076657
12.
Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Ann Transl Med
; 10(8): 441, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35571422
13.
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
J Immunother Cancer
; 10(5)2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35537782
14.
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial.
JTO Clin Res Rep
; 3(5): 100312, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35498381
15.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
J Immunother Cancer
; 10(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35017154
16.
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration.
Transl Lung Cancer Res
; 11(6): 964-974, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35832447
17.
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Clin Cancer Res
; 27(21): 5838-5846, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34400414
18.
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.
Oncoimmunology
; 10(1): 1971418, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34616588
19.
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
Clin Cancer Res
; 27(5): 1296-1304, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33323401
20.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Clin Cancer Res
; 27(4): 1003-1011, 2021 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33087333